Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Regenerative medicine is a growing field that aims to develop therapies that restore, maintain or improve tissue function. Although a number of regenerative therapies are biologically effective the vast majority of them are lacking in commercial viability. In order to translate the laboratory based biological success of regenerative medicines to large scale production capable, economic and scaleable approaches to manufacturing need to be implemented. To this end the remedi consortium are applying engineering strategies to assist in establishing regenerative medicine on a commercial footing. This paper details the application of quality engineering approaches to two stages in the manufacture of regenerative therapies: tissue scaffold fabrication and cell culture. The utility of the engineering strategies implemented is demonstrated. © 2009 Springer Berlin Heidelberg.

Original publication




Journal article


IFMBE Proceedings

Publication Date





2209 - 2212